{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T01:34:58Z","timestamp":1792892098402,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006407","name":"Natural Science Foundation of Henan Province","doi-asserted-by":"publisher","award":["252300421396"],"award-info":[{"award-number":["252300421396"]}],"id":[{"id":"10.13039\/501100006407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bcp.2026.118017","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T23:36:22Z","timestamp":1777332982000},"page":"118017","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"P2","title":["SPSB1 inhibition induces cancer immune evasion by modulating the KLF6\/PD-L1 axis in non-small cell lung cancer cells"],"prefix":"10.1016","volume":"250","author":[{"given":"Chenglai","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deqi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jincao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoyin","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1069-0370","authenticated-orcid":false,"given":"Wei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bcp.2026.118017_b0005","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"10","key":"10.1016\/j.bcp.2026.118017_b0010","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1158\/1055-9965.EPI-19-0221","article-title":"Cancer progress and priorities: lung cancer","volume":"28","author":"Schabath","year":"2019","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"2","key":"10.1016\/j.bcp.2026.118017_b0015","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.lungcan.2013.07.025","article-title":"Genetic alterations defining NSCLC subtypes and their therapeutic implications","volume":"82","author":"Pikor","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bcp.2026.118017_b0020","doi-asserted-by":"crossref","first-page":"15009","DOI":"10.1038\/nrdp.2015.9","article-title":"Non-small-cell lung cancer","volume":"1","author":"Gridelli","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"5","key":"10.1016\/j.bcp.2026.118017_b0025","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0025-6196(11)60735-0","article-title":"Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship","volume":"83","author":"Molina","year":"2008","journal-title":"Mayo Clin. Proc."},{"issue":"28","key":"10.1016\/j.bcp.2026.118017_b0030","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1200\/JCO.19.00934","article-title":"Five-year overall survival for patients with advanced non\u2012small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study","volume":"37","author":"Garon","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.bcp.2026.118017_b0035","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bcp.2026.118017_b0040","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/imm.13562","article-title":"Immunotherapeutic targets in non-small cell lung cancer","volume":"168","author":"Sadeghirad","year":"2023","journal-title":"Immunology"},{"issue":"18","key":"10.1016\/j.bcp.2026.118017_b0045","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and biochemical aspects of the PD-1 checkpoint pathway","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.bcp.2026.118017_b0050","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.bcp.2026.118017_b0055","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.immuni.2016.06.001","article-title":"Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors","volume":"44","author":"Pitt","year":"2016","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.bcp.2026.118017_b0060","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s13046-019-1192-1","article-title":"PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer","volume":"38","author":"Chen","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"23","key":"10.1016\/j.bcp.2026.118017_b0065","doi-asserted-by":"crossref","first-page":"6964","DOI":"10.1158\/0008-5472.CAN-16-0258","article-title":"Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanoma","volume":"76","author":"Clark","year":"2016","journal-title":"Cancer Res."},{"issue":"328","key":"10.1016\/j.bcp.2026.118017_b0070","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci. Transl. Med."},{"issue":"7","key":"10.1016\/j.bcp.2026.118017_b0075","first-page":"3274","article-title":"Expression of programmed death-1 ligand (PD-L1) in tumor-infiltrating lymphocytes is associated with favorable spinal chordoma prognosis","volume":"8","author":"Zou","year":"2016","journal-title":"Am. J. Transl. Res."},{"issue":"4","key":"10.1016\/j.bcp.2026.118017_b0080","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/jcsm.13252","article-title":"SPSB1-mediated inhibition of TGF-\u03b2 receptor-II impairs myogenesis in inflammation","volume":"14","author":"Li","year":"2023","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"issue":"6","key":"10.1016\/j.bcp.2026.118017_b0085","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1177\/0748730419878036","article-title":"The E3 ligases Spsb1 and Spsb4 regulate RevErb\u03b1 degradation and circadian period","volume":"34","author":"Mekbib","year":"2019","journal-title":"J. Biol. Rhythms"},{"issue":"7","key":"10.1016\/j.bcp.2026.118017_b0090","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1158\/2159-8290.CD-13-0548","article-title":"SPSB1 promotes breast cancer recurrence by potentiating c-MET signaling","volume":"4","author":"Feng","year":"2014","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.bcp.2026.118017_b0095","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/cr.2017.7","article-title":"SPSB1-mediated HnRNP A1 ubiquitylation regulates alternative splicing and cell migration in EGF signaling","volume":"27","author":"Wang","year":"2017","journal-title":"Cell Res."},{"issue":"7","key":"10.1016\/j.bcp.2026.118017_b0100","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.4049\/jimmunol.1002993","article-title":"TLR regulation of SPSB1 controls inducible nitric oxide synthase induction","volume":"187","author":"Lewis","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2026.118017_b0105","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.3389\/fimmu.2019.03121","article-title":"Cullin-5 adaptor SPSB1 controls NF-\u03baB activation downstream of multiple signaling pathways","volume":"10","author":"Georgana","year":"2019","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.bcp.2026.118017_b0110","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/s12276-021-00670-3","article-title":"MRTF-A-NF-\u03baB\/p65 axis-mediated PDL1 transcription and expression contributes to immune evasion of non-small-cell lung cancer via TGF-\u03b2","volume":"53","author":"Du","year":"2021","journal-title":"Exp. Mol. Med."},{"issue":"11","key":"10.1016\/j.bcp.2026.118017_b0115","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1158\/0008-5472.CAN-04-0185","article-title":"Kr\u00fcppel-like factor 6 is frequently down-regulated and induces apoptosis in non-small cell lung cancer cells","volume":"64","author":"Ito","year":"2004","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.bcp.2026.118017_b0120","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"issue":"3","key":"10.1016\/j.bcp.2026.118017_b0125","doi-asserted-by":"crossref","DOI":"10.1084\/jem.2021004202072022c","article-title":"Suppressive effects of the obese tumor microenvironment on CD8 T cell infiltration and effector function","volume":"219","author":"Dyck","year":"2022","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bcp.2026.118017_b0130","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.719116","article-title":"Co-stimulatory bispecific antibodies induce enhanced T cell activation and tumor cell killing in breast cancer models","volume":"12","author":"Warwas","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118017_b0135","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12943-024-02046-3","article-title":"Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches","volume":"23","author":"Liu","year":"2024","journal-title":"Mol. Cancer"},{"issue":"2","key":"10.1016\/j.bcp.2026.118017_b0140","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41418-020-00708-5","article-title":"Ubiquitination in the regulation of inflammatory cell death and cancer","volume":"28","author":"Cockram","year":"2021","journal-title":"Cell Death Differ."},{"issue":"1","key":"10.1016\/j.bcp.2026.118017_b0145","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/s41392-025-02392-8","article-title":"Targeting ubiquitination in disease and therapy","volume":"10","author":"Yang","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2026.118017_b0150","doi-asserted-by":"crossref","first-page":"4703","DOI":"10.1038\/s41467-024-48364-4","article-title":"PPIA dictates NRF2 stability to promote lung cancer progression","volume":"15","author":"Lu","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.118017_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101154","article-title":"E3 ubiquitin ligase DTX2 fosters ferroptosis resistance via suppressing NCOA4-mediated ferritinophagy in non-small cell lung cancer","volume":"77","author":"Liu","year":"2024","journal-title":"Drug Resist. Updat."},{"issue":"1","key":"10.1016\/j.bcp.2026.118017_b0160","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.cell.2021.12.005","article-title":"EMSY inhibits homologous recombination repair and the interferon response, promoting lung cancer immune evasion","volume":"185","author":"Marzio","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2026.118017_b0165","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12935-020-01240-9","article-title":"PTBP3 promotes migration of non-small cell lung cancer through regulating E-cadherin in EMT signaling pathway","volume":"20","author":"Wu","year":"2020","journal-title":"Cancer Cell Int."},{"issue":"13","key":"10.1016\/j.bcp.2026.118017_b0170","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1080\/15384101.2022.2052530","article-title":"PTBP3 mediates TGF-\u03b2-induced EMT and metastasis of lung adenocarcinoma","volume":"21","author":"Dong","year":"2022","journal-title":"Cell Cycle"},{"issue":"1","key":"10.1016\/j.bcp.2026.118017_b0175","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12935-022-02448-7","article-title":"PTBP3 regulates proliferation of lung squamous cell carcinoma cells via CDC25A-mediated cell cycle progression","volume":"22","author":"Chen","year":"2022","journal-title":"Cancer Cell Int."},{"issue":"2","key":"10.1016\/j.bcp.2026.118017_b0180","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1158\/0008-5472.CAN-17-0883","article-title":"PTBP3-Mediated Regulation of ZEB1 mRNA Stability Promotes Epithelial-Mesenchymal transition in Breast Cancer","volume":"78","author":"Hou","year":"2018","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.bcp.2026.118017_b0185","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1158\/2159-8290.CD-16-1184","article-title":"A combined PD-1\/C5a blockade synergistically protects against lung cancer growth and metastasis","volume":"7","author":"Ajona","year":"2017","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.bcp.2026.118017_b0190","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12964-023-01370-3","article-title":"Tumor immune escape: extracellular vesicles roles and therapeutics application","volume":"22","author":"Ahmadi","year":"2024","journal-title":"Cell Commun. Signal"},{"issue":"11","key":"10.1016\/j.bcp.2026.118017_b0195","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.trecan.2019.09.009","article-title":"Fibroblasts fuel immune escape in the tumor microenvironment","volume":"5","author":"De Jaeghere","year":"2019","journal-title":"Trends Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2026.118017_b0200","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12943-018-0928-4","article-title":"Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape","volume":"18","author":"Jiang","year":"2019","journal-title":"Mol. Cancer"},{"issue":"6745","key":"10.1016\/j.bcp.2026.118017_b0205","doi-asserted-by":"crossref","DOI":"10.1126\/science.adr3026","article-title":"Tumor-derived erythropoietin acts as an immunosuppressive switch in cancer immunity","volume":"388","author":"Chiu","year":"2025","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.bcp.2026.118017_b0210","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ccell.2020.02.006","article-title":"ADORA1 inhibition promotes tumor immune evasion by regulating the ATF3-PD-L1 axis","volume":"37","author":"Liu","year":"2020","journal-title":"Cancer Cell"},{"issue":"43","key":"10.1016\/j.bcp.2026.118017_b0215","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aav3937","article-title":"Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non-small cell lung cancer","volume":"5","author":"Sugiyama","year":"2020","journal-title":"Sci. Immunol."},{"issue":"17","key":"10.1016\/j.bcp.2026.118017_b0220","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bcp.2026.118017_b0225","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41588-023-01355-5","article-title":"Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer","volume":"55","author":"Ravi","year":"2023","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.bcp.2026.118017_b0230","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2026.118017_b0235","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13045-022-01242-2","article-title":"Improvement of the anticancer efficacy of PD-1\/PD-L1 blockade via combination therapy and PD-L1 regulation","volume":"15","author":"Wu","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"44","key":"10.1016\/j.bcp.2026.118017_b0240","doi-asserted-by":"crossref","first-page":"29795","DOI":"10.1074\/jbc.M802515200","article-title":"KLF6 induces apoptosis in prostate cancer cells through up-regulation of ATF3","volume":"283","author":"Huang","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.bcp.2026.118017_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2020.02.006","article-title":"ADORA1 inhibition promotes tumor immune evasion by regulating the ATF3-PD-L1 axis","volume":"37","author":"Liu","year":"2020","journal-title":"Cancer Cell"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226003503?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226003503?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:35:43Z","timestamp":1792888543000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226003503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":49,"alternative-id":["S0006295226003503"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118017","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SPSB1 inhibition induces cancer immune evasion by modulating the KLF6\/PD-L1 axis in non-small cell lung cancer cells","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118017"}}